By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Koningin Wilhelminalaan 22

Driebergen    3972 EX  The Netherlands
Phone: 31-655-764-221 Fax:


Company News
Merus Announces Final Ruling In Inequitable Conduct Case Against Regeneron (REGN) 11/4/2015 7:11:20 AM
Merus Banks 72.8 Million Euro Series C 8/26/2015 6:32:31 AM
Merus Prevails in Inequitable Conduct Case Against Regeneron (REGN) 8/10/2015 9:09:27 AM
Merus Appoints Mark Iwicki As President Of The Supervisory Board 6/1/2015 10:09:47 AM
Novartis Pharma AG (NVS) Unloads Certain Specialty Product Rights to Merus for $29.5 Million 5/22/2015 5:19:32 AM
Merus And Selexis SA Receive A € 2.1 Million Grant For Single Cell Line Manufacturing Of A Bispecific Antibody Combination To Treat Colorectal Cancer 5/20/2015 10:07:20 AM
Merus Reaches Pivotal Milestone In Bispecific Antibody Collaboration With Ono Pharmaceutical Company, Ltd. 4/8/2015 10:02:22 AM
Patent Position Of Merus' MeMo® Mouse Strengthened by Ruling of European Patent Office 9/18/2014 10:54:54 AM
ProBioGen AG And Merus Sign Deal On GlymaxX® ADCC Enhancement Technology 3/4/2014 9:46:09 AM
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies 10/23/2013 10:25:18 AM